Infection in lung transplantation;Infección en el trasplante de pulmón

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 25, Issue 10, 2007, Pages 639-650

  Gavaldà, Joan ^a   Román, Antonio ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Immunosuppression; Infection; Lung; Transplant

Indexed keywords

AMINOOXYACETIC ACID; AMPHOTERICIN B; BETA LACTAM ANTIBIOTIC; CASPOFUNGIN; GANCICLOVIR; ITRACONAZOLE; VALGANCICLOVIR; VORICONAZOLE;

BACTERIAL COLONIZATION; BACTERIAL INFECTION; BRONCHIOLITIS OBLITERANS; CYTOMEGALOVIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG GRAFT REJECTION; LUNG INFECTION; LUNG TRANSPLANTATION; MORBIDITY; MORTALITY; PREVALENCE; REVIEW; RISK FACTOR;

EID: 36849065652     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1157/13112940     Document Type: Article

References (56)

1. Kawai A, Paradis IL, Keenan RJ, Hardesty RL, Hattler BG, Pham SM, et al. Lung transplantation at the University of Pittsburgh: 1982 to 1994. Clin Transpl. 1994;111-20.
2. Knoop C, Estenne M. Acute and chronic rejection after lung transplantation. Semin Respir Crit Care Med. 2006;27:521-33.
3. Venuta F, Rendina EA, De Giacomo T, Della RG, Quattrucci S, Vizza CD, et al. Improved results with lung transplantation for cystic fibrosis. Transplant Proc. 2001;33:1632-3.
4. Corris PA, Christie JD. Update in transplantation 2006. Am J Respir Crit Care Med. 2007;175:432-5.
5. Pierson RN 3rd. Lung transplantation: current status and challenges. Transplantation. 2006;81:1609-15.
6. The Registry of the International Society for Heart and Lung Transplantation 2006. http://www.ishlt.org/
7. Al-Githmi I, Batawil N, Shigemura N, Hsin M, Lee TW, He GW, et al. Bronchiolitis obliterans following lung transplantation. Eur J Cardiothorac Surg. 2006;30:846-51.
8. Knoop C, Estenne M. Acute and chronic rejection after lung transplantation. Semin Respir Crit Care Med. 2006;27:521-33.
9. Whitehead B, Rees P, Sorensen K, Bull C, Higenbottam TW, Wallwork J, et al. Incidence of obliterative bronchiolitis after heart-lung transplantation in children. J Heart Lung Transplant. 1993;12:903-8.
10. Bando K, Paradis IL, Komatsu K, Konishi H, Matsushima M, Keena RJ, et al. Analysis of time-dependent risks for infection, rejection, and death after pulmonary transplantation. J Thorac Cardiovasc Surg. 1995;109:49-57.
11. Tikkanen JM, Kallio EA, Bruggeman CA, Koskinen PK, Lemström KB. Prevention of cytomegalovirus infection-enhanced experimental obliterative bronchiolitis by antiviral prophylaxis or immunosuppression in rat tracheal allografts. Am J Respir Crit Care Med. 2001;164:672-9.
12. Winter JB, Gouw AS, Groen M, Wildevuur C, Prop J. Respiratory viral infections aggravate airway damage caused by chronic rejection in rat lung allografts. Transplantation. 1994;57:418-22.
13. Kaiser L, Aubert JD, Pache JC, Deffernez C, Rochat T, Garbino J, et al. Chronic rhinoviral infection in lung transplant recipients. Am J Respir Crit Care Med. 2006;174:1392-9.
14. Kumar D, Erdman D, Keshavjee S, Peret T, Tellier R, Hadjiliadis D, et al. Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant. Am J Transplant. 2005;5:2031-6.
15. Khalifah AP, Hachem RR, Chakinala MM, Schechtman KB, Patterson GA, Schuster DP, et al. Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am J Respir Crit Care Med. 2004;170:181-7.
16. Billings JL, Hertz MI, Savik K, Wendt CH. Respiratory viruses and chronic rejection in lung transplant recipients. J Heart Lung Transplant. 2002;21:559-66.
17. Vilchez RA, Dauber J, Kusne S. Infectious etiology of bronchiolitis obliterans: the respiratory viruses connection - myth or reality? Am J Transplant. 2003;3:245-9.
18. Gavaldà J, Román A, Pahissa A. Risks and epidemiology of infections after lung or heart-lung transplantation. En: Bowden R, Ljungman P, Paya CV, editors. Transplant infections. 2nd ed. Philadelphia: Lippincott, Williams & Wilkins; 2003. p. 62-85.
19. Read RC, Shankar S, Rutman A, Feldman C, Yacoub M, Cole PJ, et al. Ciliary beat frequency and structure of recipient and donor epithelia following lung transplantation. Eur Respir J. 1991;4:796-801.
20. Shankar S, Fulsham L, Read RC, Theodoropoulos S, Cole PJ, Madden B, et al. Mucociliary function after lung transplantation. Transplant Proc. 1991;23:1222-3.
21. Herve P, Silbert D, Cerrina J, Simonneau G, Dartevelle P. Impairment of bronchial mucociliary clearance in long-term survivors of heart/lung and double-lung transplantation. The Paris-Sud Lung Transplant Group. Chest 1993;103:59-63.
22. Paradis IL, Marrari M, Zeevi A, Duquesnoy RJ, Griffith BP, Hardesty RL, et al. HLA phenotype of lung lavage cells following heart-lung transplantation. J Heart Transplant. 1985;4:422-5.
23. Dromer C, Nashef SA, Velly JF, Martigne C, Couraud L. Tuberculosis in transplanted lungs. J Heart Lung Transplant. 1993;12:924-7.
24. Miller RA, Lanza LA, Kline JN, Geist LJ. Mycobacterium tuberculosis in lung transplant recipients. Am J Respir Crit Care Med. 1995;152:374-6.
25. Ridgeway AL, Warner GS, Phillips P, Forshag MS, McGiffin DC, Harden JW, et al. Transmission of Mycobacterium tuberculosis to recipients of single lung transplants from the same donor. Am J Respir Crit Care Med. 1996;153:1166-8.
26. Bravo C, Roldán J, Román A, Degracia J, Majo J, Guerra J, et al. Tuberculosis in lung transplant recipients. Transplantation. 2005;79:59-64.
27. Roberts SA, Franklin JC, Mijch A, Spelman D. Nocardia infection in heart-lung transplant recipients at Alfred Hospital, Melbourne, Australia, 1989-1998. Clin Infect Dis. 2000;31:968-72.
28. Husain S, McCurry K, Dauber J, Singh N, Kusne S. Nocardia infection in lung transplant recipients. J Heart Lung Transplant. 2002;21:354-9.
29. Aguado JM, Herrero JA, Gavaldá J, Torre-Cisneros J, Blanes M, Rufi G, et al. Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Spanish Transplantation Infection Study Group, GESITRA. Transplantation. 1997;63:1278-86.
30. Cahill BC, Hibbs JR, Savik K, Juni BA, Dosland BM, Edin-Stibbe C, et al. Aspergillus airway colonization and invasive disease after lung transplantation. Chest. 1997;112:1160-4.
31. Paradowski LJ. Saprophytic fungal infections and lung transplantation - Revisited. J Heart Lung Transplant. 1997;16:524-31.
32. Westney GE, Kesten S, De Hoyos A, Chapparro C, Winton T, Maurer JR. Aspergillus infection in single and double lung transplant recipients. Transplantation. 1996;61:915-9.
33. Kramer MR, Denning DW, Marshall SE, Ross DJ, Berry G, Lewiston NJ, et al. Ulcerative tracheobronchitis after lung transplantation. A new form of invasive aspergillosis. Am Rev Resp Dis. 1991;144:552-6.
34. Ruiz I, Gavaldá J, Monforte V, Len O, Román A, Bravo C, et al. Donorto-host transmission of bacterial and fungal infections in lung transplantation. Am J Transplant. 2006;1:178-82.
35. Flume PA, Egan TM, Paradowski LJ, Detterbeck FC, Thompson JT, Yankaskas JR. Infectious complications of lung transplantation. Impact of cystic fibrosis. Am J Respir Crit Care Med. 1994;149:1601-7.
36. Doull IJ. Recent advances in cystic fibrosis. Arch Dis Child. 2001;85:62-6.
37. Husain S, Paterson DL, Studer S, Pilewski J, Crespo M, Zaldonis D, et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant. 2006;6:3008-16.
38. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356:335-47.
39. Duncan AJ, Dummer JS, Paradis IL, Dauber JH, Yousem SA, Zenati MA, et al. Cytomegalovirus infection and survival in lung transplant recipients. J Heart Lung Transplant. 1991;10:638-44.
40. Ettinger NA, Bailey TC, Trulock EP, Storch GA, Anderson D, Raab S, et al. Cytomegalovirus infection and pneumonitis. Impact after isolated lung transplantation. Washington University Lung Transplant Group. Am Rev Respir Dis. 1993;147:1017-23.
41. Soghikian MV, Valentine VG, Berry GJ, Patel HR, Robbins RC, Theodore J. Impact of ganciclovir prophylaxis on heart-lung and lung transplant recipients. J Heart Lung Transplant. 1996;15:881-7.
42. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002;34:1094-7.
43. Torre-Cisneros J, Fortún J, Aguado JM, De la Cámara R, Cisneros JM, Gavaldá J, et al. Consensus document from GESITRA-SEIMC on the prevention and treatment of cytomegalovirus infection in transplanted patients. Enferm Infecc Microbiol Clin. 2005;23:424-37.
44. Limaye AP, Raghu G, Koelle DM, Ferrenberg J, Huang ML, Boeckh M. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis. 2002;185:20-7.
45. Sharples L, McNeil K, Stewart S, Wallwork J. Risk factors for bronchiolitis obliterans: a systematic review of recent publications. J Heart Lung Transplant. 2002;21:271-81.
46. Holt ND, Gould FK, Taylor CE, Harwood JF, Freeman R, Healy MD, et al. Incidence and significance of noncytomegalovirus viral respiratory infection after adult lung transplantation. J Heart Lung Transplant. 1997;16:416-9.
47. Raj R, Frost AE. Lung retransplantation after posttransplantation lymphoproliferative disorder (PTLD): a single-center experience and review of literature of PTLD in lung transplant recipients. J Heart Lung Transplant. 2005:671-9.
48. Kumar D, Erdman D, Keshavjee S, Peret T, Tellier R, Hadjiliadis D, et al. Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant. Am J Transplant. 2005;5:2031-6.
49. Milstone AP, Brumble LM, Barnes J, Estes W, Loyd JE, Pierson RN 3rd, et al. A single-season prospective study of respiratory viral infections in lung transplant recipients. Eur Respir J. 2006;28:131-7.
50. Wendt CH, Fox JM, Hertz MI. Paramyxovirus infection in lung transplant recipients. J Heart Lung Transplant. 1995;14:479-85.
51. Glanville AR, Scott AI, Morton JM, Aboyoun CL, Plit ML, Carter IW, et al. Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant. 2005;24:2114-9.
52. McCurdy LH, Milstone A, Dummer S. Clinical features and outcomes of paramyxoviral infection in lung transplant recipients treated with ribavirin. J Heart Lung Transplant. 2003;22:745-53.
53. Soghikian MV, Valentine VG, Berry GJ, Patel HR, Robbins RC, Theodore J. Impact of ganciclovir prophylaxis on heart-lung and lung transplant recipients. J Heart Lung Transplant. 1996;15:881-7.
54. Hertz MI, Jordan C, Savik SK, Fox JM, Park S, Bolman RM 3rd, et al. Randomized trial of daily versus three-times-weekly prophylactic ganciclovir after lung and heart-lung transplantation. J Heart Lung Transplant. 1998;17:913-20.
55. Zamora MR, Nicolls MR, Hodges TN, Marquesen J, Astor T, Grazia T, et al. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant. 2004;4:1635-42.
56. Einsele H, Hebart H. CMV-specific immunotherapy. Hum Immunol. 2004;65:558-64.